company background image
BIT

Biotron ASX:BIT Stock Report

Last Price

AU$0.028

Market Cap

AU$25.3m

7D

-26.3%

1Y

-67.4%

Updated

27 Nov, 2022

Data

Company Financials
BIT fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health4/6
Dividends0/6

BIT Stock Overview

Biotron Limited, a biotechnology company, engages in developing and commercializing small molecule products to treat various viral diseases in Australia.

Biotron Limited Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Biotron
Historical stock prices
Current Share PriceAU$0.028
52 Week HighAU$0.11
52 Week LowAU$0.027
Beta-1.17
1 Month Change-24.32%
3 Month Change-52.54%
1 Year Change-67.44%
3 Year Change-53.33%
5 Year Change-6.66%
Change since IPO-93.71%

Recent News & Updates

Will Biotron (ASX:BIT) Spend Its Cash Wisely?

Jul 06
Will Biotron (ASX:BIT) Spend Its Cash Wisely?

Here's Why We're Watching Biotron's (ASX:BIT) Cash Burn Situation

Mar 17
Here's Why We're Watching Biotron's (ASX:BIT) Cash Burn Situation

Recent updates

Will Biotron (ASX:BIT) Spend Its Cash Wisely?

Jul 06
Will Biotron (ASX:BIT) Spend Its Cash Wisely?

Here's Why We're Watching Biotron's (ASX:BIT) Cash Burn Situation

Mar 17
Here's Why We're Watching Biotron's (ASX:BIT) Cash Burn Situation

Here's Why We're Not Too Worried About Biotron's (ASX:BIT) Cash Burn Situation

Nov 27
Here's Why We're Not Too Worried About Biotron's (ASX:BIT) Cash Burn Situation

Biotron (ASX:BIT) Is In A Good Position To Deliver On Growth Plans

May 26
Biotron (ASX:BIT) Is In A Good Position To Deliver On Growth Plans

We're Not Very Worried About Biotron's (ASX:BIT) Cash Burn Rate

Feb 10
We're Not Very Worried About Biotron's (ASX:BIT) Cash Burn Rate

What Can We Conclude About Biotron's (ASX:BIT) CEO Pay?

Dec 19
What Can We Conclude About Biotron's (ASX:BIT) CEO Pay?

Shareholder Returns

BITAU BiotechsAU Market
7D-26.3%1.7%1.2%
1Y-67.4%-6.8%-2.9%

Return vs Industry: BIT underperformed the Australian Biotechs industry which returned -6.8% over the past year.

Return vs Market: BIT underperformed the Australian Market which returned -2.9% over the past year.

Price Volatility

Is BIT's price volatile compared to industry and market?
BIT volatility
BIT Average Weekly Movement12.2%
Biotechs Industry Average Movement8.9%
Market Average Movement9.0%
10% most volatile stocks in AU Market16.1%
10% least volatile stocks in AU Market4.2%

Stable Share Price: BIT is not significantly more volatile than the rest of Australian stocks over the past 3 months, typically moving +/- 12% a week.

Volatility Over Time: BIT's weekly volatility (12%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
1999n/aMichelle Millerhttps://www.biotron.com.au

Biotron Limited, a biotechnology company, engages in developing and commercializing small molecule products to treat various viral diseases in Australia. The company’s lead antiviral drug is BIT225, which is in Phase II clinical trials for the treatment of SARS-CoV-2, HIV-1, and hepatitis C virus infections. Biotron Limited was incorporated in 1999 and is headquartered in Sydney, Australia.

Biotron Limited Fundamentals Summary

How do Biotron's earnings and revenue compare to its market cap?
BIT fundamental statistics
Market CapAU$25.25m
Earnings (TTM)-AU$2.78m
Revenue (TTM)AU$1.56m

16.3x

P/S Ratio

-9.1x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
BIT income statement (TTM)
RevenueAU$1.56m
Cost of RevenueAU$0
Gross ProfitAU$1.56m
Other ExpensesAU$4.34m
Earnings-AU$2.78m

Last Reported Earnings

Jun 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-0.0031
Gross Margin100.00%
Net Profit Margin-178.44%
Debt/Equity Ratio0%

How did BIT perform over the long term?

See historical performance and comparison